Addycon Holdings: Achieved Revenue of 2.638 Billion Yuan in 2025, Joint Construction Business Revenue Growth of Approximately 19.8% Year-on-Year

robot
Abstract generation in progress

Recently, Adicon Holdings released its 2025 performance report, stating that the company’s revenue was 2.638 billion yuan, a decrease of 9.5% year-on-year. Gross profit was 952 million yuan, down 13.3% year-on-year, with a gross profit margin of 36.1%.

The announcement mentioned that 2025 remains a year of adjustment for the ICL industry, but the company’s downward trend is narrowing each quarter, and operational resilience continues to strengthen.

Among them, co-construction business revenue increased approximately 19.8% year-on-year, with 69 new signed projects. During the reporting period, the company deepened cooperation with multiple key medical institutions and regional platforms, promoting joint construction of testing centers, technological upgrades, and innovative models. In September 2025, the Capital Medical University Clinical Testing Center officially began operations, creating an integrated platform for testing, diagnosis, research, education, and production, promoting the sinking of high-quality medical resources. Meanwhile, the company has successively reached strategic cooperation with An’an District Regional Medical Testing Center, Shijiazhuang Great Wall Traditional Chinese and Western Medicine Hospital, Inner Mongolia 191 International Hospital, and other medical institutions. By co-building laboratories, deploying automated testing lines, and exporting standardized management systems, they have innovated replicable models such as “hospital + third-party testing” and “hospital + third-party testing + equipment companies,” continuously improving testing quality and service efficiency, and consolidating industry leadership.

(Adicon Holdings Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin